Every material Form 8-K COMPASS Pathways plc has filed with the SEC since July 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Compass Pathways reported third quarter 2026 results. Net loss narrowed to $9.8 million from $137.7 million a year earlier, mainly because of a non-cash $40.8 million gain on warrant fair value, while operating expenses rose to $56.4 million from $40.5 million as the company prepares a potential launch. The company says its final NDA submission for COMP360 will be filed within two weeks and that cash of $444.0 million is expected to fund operations into 2028.
Net loss was $9.8 million, or $0.07 per share basic, versus $137.7 million, or $1.44 per share, a year earlier; the company attributes the decrease mainly to the warrant fair value gain.
Selling, general and administrative expenses rose to $33.0 million from $13.2 million, reflecting commercial preparedness costs; research and development fell to $23.5 million from $27.3 million.
Final NDA submission for COMP360 is expected within the next two weeks, with launch targeted for the first half of 2027, subject to FDA approval.
Cash and cash equivalents were $444.0 million at September 30, 2026, against debt of $51.0 million.
Compass Pathways reported a second-quarter 2026 net loss of $253.8 million, or $1.88 per share, up from $38.4 million, or $0.41 per share, a year earlier. The filing attributes the increase mainly to a non-cash $205.6 million loss from fair value changes in warrants, which move with the share price, while operating expenses were $52.4 million. The company says it expects to submit its final NDA for COMP360 in Q4 2026 and launch in the first half of 2027, subject to FDA approval and DEA rescheduling.
Q2 2026 net loss was $253.8 million ($1.88 per share), versus $38.4 million ($0.41 per share) in Q2 2025; the warrant fair value change was a $205.6 million loss.
Research and development expenses were $29.2 million, down from $30.3 million; general and administrative expenses rose to $23.2 million from $12.6 million, tied to commercial preparedness.
Cash and cash equivalents were $433.3 million at June 30, 2026, up from $149.6 million at December 31, 2025; debt was $50.7 million.
The company expects its cash position to fund operations and capital expenditures into 2028.
Compass Pathways reported 26-week results from the second Phase 3 COMP006 trial of COMP360 in treatment-resistant depression, saying they confirm rapid onset and durable response. The company said its rolling NDA submission is underway, with final submission expected in Q4 2026 and launch expected in the first half of 2027, subject to FDA approval and DEA rescheduling.
39% of participants in the 25 mg arm reached a clinically meaningful MADRS reduction of at least 25% by Week 6 and maintained benefit through at least Week 26
COMP006 enrolled 581 dosed participants; serious adverse events were 6.3% in the 1 mg arm and 5.7% in the 25 mg arm over 26 weeks
Final NDA submission is expected in Q4 2026, with launch anticipated in the first half of 2027 if FDA approved
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every COMPASS Pathways plc filing is on SEC EDGAR ↗. 8-K briefs of other companies →